Course: Development of High-Dose Biologics Dosage Forms
Dinner Short Course: Organized by Cambridge Healthtech Institute
Development of High-Dose Biologics Dosage Forms
Tuesday, May 6, 2014 | 6:00-9:00 pm
Seaport World Trade Center, Boston, MA (Dinner will be served)
Topics to be covered:
Why are high concentration dosage forms increasingly becoming important?
What are the challenges of high doses? What factors define them?
Viscosity limitations in production and delivery
Current state of the art with devices for high-volume injections
• Current understanding of what causes high viscosity in mAbs
• Studies probing underlying molecular mechanisms
• Engineering high viscosity causing molecules
• High-throughput (HT) methods for measuring viscosity: Ensuring accuracy and precision
• HT screening tools for predicting viscosity
• Excipients for reducing viscosity
• Aggregation in high-concentration formulations
• Temperature dependence of viscosity
Alternate methods of producing high concentration MAb solutions
Christopher M. Olsen, Ph.D., Senior Scientist, CMC Analytical Chemistry, Alcon Laboratories, Inc., a
Division of Novartis
Nicholas J. Darton, Ph.D., Platform Manager, Arecor Ltd.
How to Register:
This course is part of the Biologics Formulation & Delivery Summit.